The antiviral drug remdesivir has shown significant results in monkeys that had been infected with the novel coronavirus, a study by the National Institutes of Health (NIH) has revealed.
The study, led by the its National Institute of Allergy and Infectious Diseases (NIAID) involved two groups of six rhesus macaque monkeys that were intentionally infected with the respiratory disease. One group was treated with remdesivir while the second was not.
The first group of monkeys was given its first dose of the drug intravenously 12 hours after the initial infection, and then every day for a further six days. Twelve hours after the initial treatment, symptoms of COVID-19 in the monkeys had significantly improved and their conditions continued to improve during the rest of the trial.
At the end of the test, just one of the six animals treated with remdesivir displayed mild difficulty breathing, while all six animals in the untreated group had difficulty breathing.
The amount of virus found in their lungs was significantly lower in the treatment group compared to the untreated group, the study stated, and the coronavirus caused less damage to the lungs in the treated monkeys than in the untreated ones. – READ MORE
Listen to the insightful Thomas Paine Podcast Below --